+49 (0) 211 247 907 70
Menu Close Menu

Chelsea

Frenchie
mathias Hennebellle
Share

Performance

  • +31.4 %
    since 2014-10-31
  • +21,2 %
    1 Jahr
    -0,22 %
    Heute
    -9,0 %
    Max Verlust (bisher)
    0,5x
    Risiko-Faktor
    ;
    You want access to all the information?
    • All key figures
    • The current portfolio
    • Every trade in real time
    Register
Portfolio

Trade Idea

Chelsea Wikifolio stellt einen Panel von Aktien mit Dynamischem Wachstum dar.
In diesem Folio sollte ein geringe Diversifizierung stattfinden.
Es bedeutet nur ein geringe Zahl von unterschiedliche Unternehmen werden in dem Folio enthalten sein.

Unternehmen aus der ganzen Welt, auf allen Börsen und Sektoren sollten in Chelsea einbehalten werden. Damit behaltet der Folio eine Flexibilität und frei Handel Bewegung.


Die Wertpapiere sollten kurzfristig oder langfristig behalten. Die Dauer wie lang ein Wertpapier in dem Wikifolio bleiben wird , basiert sich auf meine persönliche Expertise, bzw. Wissen über das Unternehmen.

Aufgrund regelmässige Screening , Beobachtung und Trendsanalyse werden die Entscheidungsfindung getroffen.






show more
This content is not available in the current language.
Master data
Symbol
WF0CHELSEA
Date created
2014-10-31
Index level
High watermark
149.5

Rules

wikifolio labels

Investment Universe

Trader

Frenchie
mathias Hennebellle
Registered since 2014-08-28
[Beschreiben Sie, Ihre Erfahrung mit Wertpapieren….] [Beschreiben Sie, wie Sie zum Handel mit Wertpapieren gekommen sind….] [Beschreiben Sie, welche Trading-Erfolge Sie in der Vergangenheit hatten......] [Beschreiben Sie, Ihre Gedanken zur aktuellen Marktlage….] [Beschreiben Sie, wie viel Zeit sie für Ihre Handelsidee aufwenden….]
Show profile

Decision making

  • Technical analysis
  • Fundamental analysis
  • Other analysis

Comments

Comment on ABBVIE INC

AbbVie Inc. (ABBV) has agreed to provide its breakthrough, $1,000-a-day hepatitis C treatment to state-based HIV drug programs at a substantial discount, according to a group that negotiates drug pricing for the programs. The ADAP Crisis Task Force negotiates for the 50-plus such programs and served about 150,000 patients in June 2013, said Britten Pund, associate director of health-care access for the National Alliance of State & Territorial AIDS Directors. The group doesn’t have any deal with Gilead Sciences Inc. (GILD), which sells the competing medicines Sovaldi and Harvoni. AbbVie’s drug, Viekira Pak, requires patients to take more pills a day than Gilead’s treatment. “The task force had previously tried to negotiate with Gilead on the price of Sovaldi, and Gilead had declined to negotiate,” Pund said in a telephone interview. “We did not have a specific conversations about Harvoni, but we hope to reignite those conversations.” Cara Miller, a Gilead spokeswoman, declined to comment. About 30 percent of people with HIV are also estimated to be infected with hepatitis C, according to the group. AbbVie and Gilead have been negotiating with insurers and pharmacy benefit managers to gain traction on lists of drugs covered by health insurers and state programs. Aetna Inc., for example, announced a deal Friday with Gilead giving preference to its drugs. show more

Comment on LUFTHANSA AG VNA O.N.

Oben im Dax steht die Deutsche Lufthansa. Die Airline bekommt derzeit etwas Luft in den Tarifverhandlungen mit ihren Flugbegleitern: Die setzen jetzt auf einen Schlichter, was mögliche Streiks erst einmal unwahrscheinlich macht. Anleger danken das mit +4,65 Prozent beim Aktienkurs show more

Comment on CELGENE CORP. DL-,01

Celgene announced Monday preliminary earnings for 2014 and said that it expects its revenue to double to $20 billion by 2020. Meanwhile, the company estimated that its haematology business will grow to $14.8 billion by the same time, while earnings are expected to total $12.50 per share. Analysts had forecast earnings of $11.42 per share on $17.9 billion in revenue. show more

Comment on ABBVIE INC

AbbVie has delivered strong performance in our first two years as an independent company and we expect to continue building on that momentum in 2015 with a return to top-tier growth," commented CEO Richard A. Gonzalez. The company indicated that growth will be led by Humira and the launch of its oral hepatitis C regimen Viekira, partially offset by declines in several products that face generic competition, including AndroGel. AbbVie added that it "intends to further refine its 2015 guidance as the...launch progresses" for Viekira. show more
Don't miss out on anything!
To see all comments of this wikifolio please create an account.
Register

Top wikifolios

Now investable

More wikifolios